First subjects dosed in first-in-human Phase 1 c
Author: Michael
DeepLife secures $10m to advance AI platform des
Research links hidden visceral fat to abnormal p
Company targets metabolic, immunological and neu
Spain-based fund targets challenges posed by agi
How professional care can integrate personalized
Crypto investor-backed LongGame aims to fund tec
Clinical trial of company’s osteoporosis drug
Dr Eric Verdin of The Buck Institute for Researc
Promising data from Phase 2 study in myelodyspla